title: Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus.
abstract: OBJECTIVE
  The aim of the study was to assess the concentration of anti-oxidized low-density lipoprotein (anti-oxLDL) antibodies and antibodies against oxLDL-beta2GPI (oxLDL-beta 2 glycoprotein I) complexes in the serum of patients with systemic lupus erythematosus (SLE). Correlations between clinical and laboratory factors and the intima media thickness (IMT) were also investigated.
  
  
  METHODS
  The study included 16 patients (14 females, 2 males) with an established diagnosis of SLE. The mean disease duration was 6.3 years (range: 2-23 years). Thirteen age-matched healthy volunteers comprised the control group. IMT, the concentration of anti-oxLDL and anti-oxLDL-beta2GPI antibodies and lipid profile were assesed. Data concerning other cardiovascular risk factors were also collected.
  
  
  RESULTS
  In the SLE group the intima media was significantly thicker than in control group. In the SLE group a statistically significant positive correlation was noted between age and mean IMT. Immunological assays revealed elevated serum concentration of anti-oxLDL antibodies in the SLE group; serum concentration of IgG anti-oxLDL-beta2GPI antibodies and IgM anti-oxLDL-beta2GPI antibodies were also elevated in the SLE group compared to the controls. There was a statistically significant positive correlation between LDL concentration and anti-oxLDL antibody concentration in the SLE group.
  
  
  CONCLUSIONS
  The study findings support the thesis that cardiovasular risk is significantly higher in SLE patients. Elevated concentrations of anti-oxLDL antibodies, IgG anti-oxLDL-beta2GPI antibodies and IgM anti-oxLDL-beta2GPI antibodies were detected in the SLE group, which may contribute to the elevated cardiovascular risk in SLE patients.
authors.affiliation: Department of Pharmacology, Wroclaw Medical University, Poland. betanowak@interia.pl
authors.forename: Beata
authors.initials: B
authors.lastname: Nowak
authors.forename: Magdalena
authors.initials: M
authors.lastname: Szmyrka-Kaczmarek
authors.forename: Anna
authors.initials: A
authors.lastname: Durazińska
authors.forename: Rafał
authors.initials: R
authors.lastname: Płaksej
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Borysewicz
authors.forename: Lucyna
authors.initials: L
authors.lastname: Korman
authors.forename: Piotr
authors.initials: P
authors.lastname: Wiland
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000209:etiology; D059168:Carotid Intima-Media Thickness; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011044:Poland; D018570:Risk Assessment; D012307:Risk Factors; D015854:Up-Regulation; D053482:beta 2-Glycoprotein I / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D008077:Lipoproteins, LDL; D053482:beta 2-Glycoprotein I; C099252:oxidized low density lipoprotein